Immune checkpoint inhibitors for recurrent endometrial cancer

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73
   PubMed Web of Science ®Google Scholar
• Church DN, Briggs SEW, Palles C, et al. DNA polymerase epsilon and delta exonuclease domain mutations in endometrial cancer. Hum Mol Genet. 2013;22:2820–2828.
   PubMed Web of Science ®Google Scholar
• Pakish JB, Zhang Q, Chen Z, et al. Immune microenvironment in microsatellite-instable endometrial cancers: hereditary or sporadic origin matters. Clin Cancer Res. 2017;23:4473–4481
   PubMed Web of Science ®Google Scholar
• Gordhandas S, Kahn RM, Gamble C, et al. Clinicopathologic features of endometrial cancer with mismatch repair deficiency. Ecancermedicalscience. 2020;14:1061.
   PubMed Web of Science ®Google Scholar
• Mpakali A, Stratikos E. The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy. Cancers (Basel). 2021;13:134.
   Web of Science ®Google Scholar
• Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106:255–258.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity. 2010;33:464–478.
   PubMed Web of Science ®Google Scholar
• Cao W, Ma, X, and Fischer, JV, et al. Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomark Res. 2021;9:49
   PubMed Web of Science ®Google Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231–235.
   PubMed Web of Science ®Google Scholar
• Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6:202–216.
   PubMed Web of Science ®Google Scholar
• Casey SC, Tong L, Li Y, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227–231.
   PubMed Web of Science ®Google Scholar
• Rosenthal R, Cadieux EL, Salgado R, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567:479–485.
   PubMed Web of Science ®Google Scholar
• DuPage M, Mazumdar C, Schmidt LM, et al. Expression of tumour-specific antigens underlies cancer immunoediting. Nature. 2012;482:405–409.
   PubMed Web of Science ®Google Scholar
• Montesion M, Murugesan K, Jin DX, et al. Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov. 2021;11:282–292.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Rosenthal R, Hiley CT, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171:1259–1271 e1211.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227–242.
   PubMed Web of Science ®Google Scholar
• Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:155.
   PubMed Web of Science ®Google Scholar
• Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996;183:2541–2550.
   PubMed Web of Science ®Google Scholar
• van der Merwe PA, Bodian DL, Daenke S, et al. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med. 1997;185:393–403.
   PubMed Web of Science ®Google Scholar
• Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209:1201–1217.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153–167.
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Muto G. TGF-beta function in immune suppression. Curr Top Microbiol Immunol. 2011;350:127–147.
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150–4166.
   PubMed Web of Science ®Google Scholar
• Lob S, Konigsrainer A, Rammensee HG, et al. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer. 2009;9:445–452.
   PubMed Web of Science ®Google Scholar
• Green AK, Feinberg J, Makker V. A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book. 2020;40:1–7.
   PubMedGoogle Scholar
• Talhouk A, Derocher H, Schmidt P, et al. Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin Cancer Res. 2019;25:2537–2548
   PubMed Web of Science ®Google Scholar
• van Gool IC, Eggink FA, Freeman-Mills L, et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res. 2015;21:3347–3355.
   PubMed Web of Science ®Google Scholar
• Bellone S, Centritto F, Black J, et al. Polymerase epsilon (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecol Oncol. 2015;138:11–17.
   PubMed Web of Science ®Google Scholar
• Mullen MM, Mutch DG. Endometrial tumor immune response: predictive biomarker of response to immunotherapy. Clin Cancer Res. 2019;25:2366–2368.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520.
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang Y-J, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 Study. J Clin Oncol. 2017;35:2535–2541.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1–10
   PubMed Web of Science ®Google Scholar
• Bellone S, Roque DM, Siegel ER, et al. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Ann Oncol. 2021;32:1045–1046.
   PubMed Web of Science ®Google Scholar
• MK-3475 immunotherapy in endometrial carcinoma. https://clinicaltrials.gov/ct2/show/NCT02630823&gt
   Google Scholar
• A study of pembrolizumab on the tumoral immunoprofile of gynecologic cancers [cited 2022 Feb 1] . https://clinicaltrials.gov/ct2/show/NCT02728830
   Google Scholar
• Santin AD, Bellone S, Buza N, et al. Regression of Chemotherapy-Resistant Polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res. 2016;22:5682–5687
   PubMed Web of Science ®Google Scholar
• Tamura K, Hasegawa K, Katsumata N, et al. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. Cancer Sci. 2019;110:2894–2904.
   PubMed Web of Science ®Google Scholar
• Azad NS, Gray RJ, Overman MJ, et al. Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study. J Clin Oncol. 2020;38:214–222.
   PubMed Web of Science ®Google Scholar
• Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 2020;6:1766–1772.
   PubMed Web of Science ®Google Scholar
• Oaknin A, et al. in ESMO Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET 2020. Available from: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-antitumor-activity-of-dostarlimab-in-patients-pts-with-advanced-or-recurrent-dna-mismatch-repair-deficient-dmmr-or-proficient-mmrp .
   Google Scholar
• Antill Y, Kok P-S, Robledo K, et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer. 2021;9. doi:https://doi.org/10.1136/jitc-2020-002255.
   Google Scholar
• Liu JF, Gordon M, Veneris J, et al. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019;154:314–322.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol. 2019;37:2786–2794
   PubMed Web of Science ®Google Scholar
• Cesaire M, Thariat J, Candéias SM, et al. Combining PARP inhibition, radiation, and immunotherapy: a possible strategy to improve the treatment of cancer? Int J Mol Sci. 2018;19:3793.
   PubMed Web of Science ®Google Scholar
• Pantelidou C, Sonzogni O, De Oliveria Taveira M, et al. PARP inhibitor efficacy depends on CD8 + T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 2019;9:722–737.
   PubMed Web of Science ®Google Scholar
• Post CCB, Westermann AM, Bosse T, et al. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Crit Rev Oncol Hematol. 2020;152:102973.
   PubMed Web of Science ®Google Scholar
• The EndoBARR trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (EndoBARR) [cited 2022 Feb 1] . https://clinicaltrials.gov/ct2/show/results/NCT03694262?view=results
   Google Scholar
• Durvalumab with or without olaparib as maintenance therapy after first-line treatment of advanced and recurrent endometrial cancer (DUO-E) [cited 2022 Feb 1] . https://www.clinicaltrials.gov/ct2/show/NCT04269200
   Google Scholar
• Zimmer AS, Nichols E, Cimino-Mathews A, et al. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses. J Immunother Cancer. 2019;7:197.
   PubMed Web of Science ®Google Scholar
• Lee JM, Cimino-Mathews A, Peer CJ, et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-Ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women’s cancers: a dose-escalation, phase i study. J Clin Oncol. 2017;35:2193–2202.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Buchbinder EI. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol. 2015;5:202.
   PubMed Web of Science ®Google Scholar
• Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:711–718.
   PubMed Web of Science ®Google Scholar
• KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) significantly improved progression-free survival and overall survival versus chemotherapy in patients with advanced endometrial cancer following prior platinum-based chemotherapy in phase 3 study [cited 2022 Feb 7] . https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-significantly-improved-progression-free-survival-and-overall-survival-versus-chemotherapy-in-patients-with-advanced-endometrial-cancer-fo/&gt
   Google Scholar
• FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pembrolizumab-and-lenvatinib-advanced-endometrial-carcinoma
   Google Scholar
• Lheureux S, Matei D, Konstantinopoulos PA, et al. A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. J clin oncol. 2020;38: 6010-6010.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8:151–160.
   PubMed Web of Science ®Google Scholar
• Samanta D, Park Y, Ni X, et al. Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells. Proc Natl Acad Sci U S A. 2018;115:E1239–E1248.
   PubMed Web of Science ®Google Scholar
• Peng J, Hamanishi J, Matsumura N, et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 2015;75:5034–5045.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan R, Assudani D, Nagaraj S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest. 2010;120:1111–1124.
   PubMed Web of Science ®Google Scholar
• Liu WM, Fowler DW, Smith P, et al. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010;102:115–123.
   PubMed Web of Science ®Google Scholar
• Pineda MJ, Schilder J, Hill EK, et al. A big ten cancer research consortium phase II trial of pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer. J clin oncol. 2020;38: 6022-6022.
   Web of Science ®Google Scholar
• Deng L, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–695.
   PubMed Web of Science ®Google Scholar
• Gameiro SR, Jammeh ML, Wattenberg MM, et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5:403–416.
   PubMed Web of Science ®Google Scholar
• Sharabi AB, Nirschl, CJ, and Kochel, CM, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3:345–355.
   PubMed Web of Science ®Google Scholar
• Reits EA, Hodge, JW, and Herberts, CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259–1271.
   PubMed Web of Science ®Google Scholar
• Study of pembrolizumab (MK-3475) in combination with adjuvant chemotherapy with or without radiotherapy in participants with newly diagnosed endometrial cancer after surgery with curative intent (MK-3475-B21/KEYNOTE-B21/ENGOT-en11/GOG-3053) [cited 2022 Feb 1] . https://clinicaltrials.gov/ct2/show/NCT04634877
   Google Scholar
• Frontline immunotherapy combined with radiation and chemotherapy in high risk endometrial cancer (FIERCE) [cited 2022 Feb 1] . https://clinicaltrials.gov/ct2/show/NCT03932409
   Google Scholar
• Bogani G, Ray-Coquard, I, and Concin, N, et al. Uterine serous carcinoma. Gynecol Oncol. 2021;162:226–234.
   PubMed Web of Science ®Google Scholar
• Soslow RA, Tornos, C, and Park, KJ, et al. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists. Int J Gynecol Pathol. 2019;38(Suppl 1):S64–S74.
   PubMed Web of Science ®Google Scholar
• Salani R, Khanna N, Frimer M, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: society of gynecologic oncology (SGO) recommendations. Gynecol Oncol. 2017;146:3–10.
   PubMed Web of Science ®Google Scholar
• Rubinstein MM, Caird, I, and Zhou, Q, et al. A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma. J clin oncol. 2019;37: 5582-5582.
   Web of Science ®Google Scholar
• A study of targeted agents with atezolizumab for patients with recurrent or persistent endometrial cancer (EndoMAP) [cited 2022 Feb 2] . https://clinicaltrials.gov/ct2/show/NCT04486352&gt
   Google Scholar
• Santin AD, Hermonat, PL, and Ravaggi, A, et al. Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endometrial cancer. Gynecol Obstet Invest. 2000;49:194–203.
   PubMed Web of Science ®Google Scholar
• Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 2021;28:513–527.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Garcia A, Sharma, P, and Poussin, M, et al. CAR T cells targeting MISIIR for the treatment of ovarian cancer and other gynecologic malignancies. Mol Ther. 2020;28:548–560.
   PubMed Web of Science ®Google Scholar
• Thomas R, Al-Khadairi, G, and Roelands, J, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol. 2018;9:947.
   PubMed Web of Science ®Google Scholar
• Talhouk A, McConechy, MK, and Leung, S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113:299–310
   PubMed Web of Science ®Google Scholar
• Kommoss S, McConechy, MK, and Kommoss, F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29:1180–1188.
   PubMed Web of Science ®Google Scholar
• Temko D, Van Gool, IC, and Rayner, E, et al. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. J Pathol. 2018;245:283–296.
   PubMed Web of Science ®Google Scholar
• Bellone S Bignotti, E, and Lonardi, S, et al. Polymerase epsilon (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecol Oncol. 2017;144:146–152.
   PubMed Web of Science ®Google Scholar
• Howitt BE, Shukla, SA, and Sholl, LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1:1319–1323.
   PubMed Web of Science ®Google Scholar
• Bonneville R Krook, MA, and Kautto, EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017. doi:https://doi.org/10.1200/PO.17.00073.
   PubMed Web of Science ®Google Scholar